Featured Research

from universities, journals, and other organizations

New Treatment Boosts Bone Healing And Regrowth

Date:
January 12, 2008
Source:
University of Alabama at Birmingham
Summary:
A drug originally used to treat iron poisoning can significantly boost the body's ability to heal and regrow injured bones, according to a new study. Bone density following the new treatment more than doubled. Researchers found new blood vessel growth, necessary for bone healing, was achieved through a cell pathway.

A drug originally used to treat iron poisoning can significantly boost the body’s own ability to heal and re-grow injured bones, according to researchers at the University of Alabama at Birmingham (UAB).

The researchers injected the drug deferoxamine (DF), which is designed to reduce iron overload, into injured mouse bones. They found DF triggered the growth of new blood vessels, which in turn kicked off bone re-growth and healing.

In the study, bone density surrounding the injury more than doubled to 2.6 cubic millimeters in treated bones compared to 1.2 cubic millimeters in untreated bones, the researchers said. The new blood vessel growth and bone healing was achieved through a cell pathway that helps the body respond to low oxygen levels, a common problem when blood supply is affected by bone fracture and disease.

Findings on this cell pathway have broad implications for improving treatment of bone fractures, bone disease and other musculoskeletal disorders, said Shawn Gilbert, M.D., an assistant professor of orthopedic surgery in the UAB School of Medicine, and Chao Wan, M.D. Ph.D., an instructor in the UAB Department of Pathology, both co-authors on the study.

“With DF activating this pathway, we’ve proven a significant point – it is possible to explore new, safe and more affordable ways kick-start bone repair,” Gilbert said.

“Current treatments use complex proteins, which are expensive to make and cost thousands of dollars per dose. The type of agent used in this study is a simple, small molecule drug that costs hundreds, not thousands,” Gilbert said.

“The results from this study are a milestone for future studies looking at other compounds and agents to improve new-blood-vessel growth in skeletal and other tissues that need adequate blood supply to regenerate,” Wan said.

The UAB tests were performed in conjunction with a bone lengthening procedure commonly used in children and adults, and has proven to aid bone healing. The study mice were anesthetized for surgery, and one leg bone was cut clean through and a pulling device attached temporarily to stretch the bone gap for the next 10 days.

During the stretching, the bone gap was injected with five DF doses. Two weeks after the last DF dose, X-rays of the mice legs were taken to measure bone regeneration.

DF is a drug that binds to excess iron in the body and helps with excretion through the bowels and bladder, a process sometimes called iron chelation. DF is used to treat a variety of medical conditions, including iron overload, transfusion-related blood poisoning and in combination with dialysis.

In the findings on post-treatment increased bone density, the UAB researchers found significant increases in the number of new blood vessels, and excellent connectivity between those vessels. The new blood vessels are required regenerate bone of equal or better strength than the original bones.

Gilbert said it follows that this cell pathway is a prime target for future human studies using DF and other drugs to strengthen the body’s bone-healing potential, especially since poor blood supply is common in fractures and bone disease.

The UAB findings are published in the online version of the journal Proceedings of the National Academy of Sciences and will soon appear in a print edition.

The research team included UAB investigators from the departments of Surgery, Pathology, and Biomedical Engineering and from Children’s Hospital of Alabama, Birmingham, the Veterans Affairs Medical Center in Birmingham and Boston University Medical Center. Funding for the study came from the National Institutes of Health.


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Cite This Page:

University of Alabama at Birmingham. "New Treatment Boosts Bone Healing And Regrowth." ScienceDaily. ScienceDaily, 12 January 2008. <www.sciencedaily.com/releases/2008/01/080110085148.htm>.
University of Alabama at Birmingham. (2008, January 12). New Treatment Boosts Bone Healing And Regrowth. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2008/01/080110085148.htm
University of Alabama at Birmingham. "New Treatment Boosts Bone Healing And Regrowth." ScienceDaily. www.sciencedaily.com/releases/2008/01/080110085148.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins